[{"id":"8e333d31-cdb1-4edd-a209-db63d88f24e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087263","created_at":"2023-10-17T15:12:53.355Z","updated_at":"2025-02-25T17:26:29.076Z","phase":"Phase 2","brief_title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","source_id_and_acronym":"NCT06087263","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SDHB","pipe":" | ","alterations":" KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/18/2024","start_date":" 06/18/2024","primary_txt":" Primary completion: 07/01/2032","primary_completion_date":" 07/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2025-01-10"},{"id":"6e09028c-351c-49a3-ae4b-ecc4e168b4c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04267120","created_at":"2021-01-18T20:44:00.448Z","updated_at":"2025-02-25T16:10:00.555Z","phase":"Phase 2","brief_title":"Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)","source_id_and_acronym":"NCT04267120","lead_sponsor":"Washington University School of Medicine","biomarkers":" SDHB • TSC1","pipe":" | ","alterations":" TSC1 deletion","tags":["SDHB • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 07/09/2024","primary_completion_date":" 07/09/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-26"},{"id":"28905f7c-1ba3-4c54-b0ee-8bfef8ba9fd0","acronym":"CDFF332A12101","url":"https://clinicaltrials.gov/study/NCT04895748","created_at":"2021-05-20T11:54:08.339Z","updated_at":"2024-07-02T16:35:03.755Z","phase":"Phase 1","brief_title":"DFF332 as a Single Agent and in Combination With Everolimus \u0026 Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer \u0026 Other Malignancies","source_id_and_acronym":"NCT04895748 - CDFF332A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-14"},{"id":"bdeeb997-777f-49f0-a14b-737c55f2bc1a","acronym":"MyVHL","url":"https://clinicaltrials.gov/study/NCT03749980","created_at":"2021-01-18T18:23:13.417Z","updated_at":"2024-07-02T16:35:07.423Z","phase":"","brief_title":"MyVHL: Patient Natural History Study","source_id_and_acronym":"NCT03749980 - MyVHL","lead_sponsor":"Joshua Mann, MPH","biomarkers":" SDHB","pipe":"","alterations":" ","tags":["SDHB"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-04-26"},{"id":"57d72b12-2ee4-465b-8e35-96a6d9527fcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03594422","created_at":"2021-01-18T17:40:27.278Z","updated_at":"2024-07-02T16:35:14.185Z","phase":"Phase 1","brief_title":"A Study of HQP1351 in Patients With GIST or Other Solid Tumors","source_id_and_acronym":"NCT03594422","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" NF1 • SDHB","pipe":" | ","alterations":" NF1 mutation","tags":["NF1 • SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-03-19"},{"id":"c53db940-a183-41f3-86f8-5e3dfedd1e7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03008369","created_at":"2024-02-20T23:29:06.708Z","updated_at":"2024-07-02T16:35:18.611Z","phase":"Phase 2","brief_title":"Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03008369","lead_sponsor":"Mayo Clinic","biomarkers":" SDHB • SDHD","pipe":"","alterations":" ","tags":["SDHB • SDHD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 09/28/2022","study_completion_date":" 09/28/2022","last_update_posted":"2024-02-20"},{"id":"d5162325-5b3c-4d42-94a5-aa1bdf6c5de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03839498","created_at":"2021-01-18T18:57:18.296Z","updated_at":"2024-07-02T16:36:02.878Z","phase":"Phase 2","brief_title":"Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma","source_id_and_acronym":"NCT03839498","lead_sponsor":"Columbia University","biomarkers":" SDHB","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/22/2019","start_date":" 01/22/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2022-10-07"},{"id":"1189ff20-2bb4-4fb5-bc1b-400560954d19","acronym":"","url":"https://clinicaltrials.gov/study/NCT01967576","created_at":"2021-01-18T08:56:37.608Z","updated_at":"2024-07-02T16:36:36.550Z","phase":"Phase 2","brief_title":"Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma","source_id_and_acronym":"NCT01967576","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SDHB","pipe":"","alterations":" ","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/19/2013","start_date":" 10/19/2013","primary_txt":" Primary completion: 06/29/2015","primary_completion_date":" 06/29/2015","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2021-01-06"}]